Tomoyuki Nishida
Overview
Explore the profile of Tomoyuki Nishida including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
332
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kadowaki T, Lee S, Ogawa W, Nishida T, Overvad M, Tobe K, et al.
Obes Res Clin Pract
. 2025 Jan;
18(6):457-464.
PMID: 39824696
Objective: To explore the effects of semaglutide versus placebo on body weight (BW) by subgroups of baseline characteristics. Methods: In STEP 6, Japanese and Korean adults with overweight or obesity...
2.
Lingvay I, Benamar M, Chen L, Fu A, Jodar E, Nishida T, et al.
Diabetologia
. 2025 Jan;
PMID: 39820580
Aims/hypothesis: COMBINE 2 assessed the efficacy and safety of once-weekly IcoSema (a combination therapy of basal insulin icodec and semaglutide) vs once-weekly semaglutide (a glucagon-like peptide-1 analogue) 1.0 mg in...
3.
Eto T, Haranaka M, Kristensen N, Navarria A, Nishida T, Ribel-Madsen R, et al.
J Diabetes Investig
. 2024 Dec;
16(3):434-441.
PMID: 39665530
Introduction: Insulin icodec is a basal insulin designed for once-weekly administration. This study assessed the pharmacological properties of icodec in Japanese individuals with type 1 diabetes (T1D). Materials And Methods:...
4.
Bergenstal R, Asbjornsdottir B, Watt S, Lingvay I, Mader J, Nishida T, et al.
Lancet Diabetes Endocrinol
. 2024 Oct;
12(11):799-810.
PMID: 39374601
Background: Continuous glucose monitoring (CGM) can provide a comprehensive assessment of glycaemic control. This exploratory analysis of the ONWARDS 1 trial assessed CGM-based metrics and CGM-derived hypoglycaemia duration in insulin-naive...
5.
Watada H, Asbjornsdottir B, Nishida T, Nishimura R, Yamamoto Y, Yamauchi T, et al.
Diabetes Obes Metab
. 2024 Sep;
26(12):5882-5895.
PMID: 39344833
Aim: To explore the efficacy and safety of once-weekly insulin icodec (icodec) in Japanese adults (≥20 years old) with type 2 diabetes from the global ONWARDS 1, 2 and 4...
6.
Rosenstock J, Bain S, Gowda A, Jodar E, Liang B, Lingvay I, et al.
N Engl J Med
. 2023 Jun;
389(4):297-308.
PMID: 37356066
Background: Insulin icodec is an investigational once-weekly basal insulin analogue for diabetes management. Methods: We conducted a 78-week randomized, open-label, treat-to-target phase 3a trial (including a 52-week main phase and...
7.
Araki E, Harashima S, Nishida T, Nakamura J
J Diabetes Investig
. 2022 Oct;
13(12):1971-1980.
PMID: 36222597
Aims/introduction: The etiology and treatment of type 2 diabetes might differ between specific populations. This post-hoc exploratory analysis assessed the efficacy and safety of once-weekly subcutaneous semaglutide vs comparators in...
8.
Yabe D, Yamada Y, Kaku K, Nishida T, Sato T, Seino Y
J Diabetes Investig
. 2022 Feb;
13(7):1161-1174.
PMID: 35174649
Aims/introduction: Many East Asians with type 2 diabetes are elderly and have a low body mass index (BMI), especially in 'super-aged' populations, such as Japan. This post-hoc analysis assessed once-weekly...
9.
Kadowaki T, Isendahl J, Khalid U, Lee S, Nishida T, Ogawa W, et al.
Lancet Diabetes Endocrinol
. 2022 Feb;
10(3):193-206.
PMID: 35131037
Background: Semaglutide 2·4 mg once weekly has been investigated for weight management in global populations. Differences exist between Asian and non-Asian populations in terms of body composition and definitions of...
10.
Pei Y, Agner B, Luo B, Dong X, Li D, Liu J, et al.
Diabetes Obes Metab
. 2021 Aug;
23(12):2687-2696.
PMID: 34387411
Aim: To assess the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin degludec (degludec) in Chinese people with type 2 diabetes (T2D) treated with basal insulin. Materials And Methods:...